|
Oncothyreon has granted a license to Merck KGaA of Darmstadt, Germany (Merck KGaA) for the global development of Stimuvax®, a therapeutic vaccine currently in Phase 3 clinical trials for non-small cell lung cancer and breast cancer.
Merck KGaA is responsible worldwide for clinical development, manufacturing, including process development and scale-up for commercial manufacturing, and marketing.
Oncothyreon will receive significant cash payments based on the achievement of certain process transfer events, for BLA submission for first and second cancer indications, for regulatory approval for first and second cancer indications, and for sales milestones. Oncothyreon will receive a royalty based on net sales.
|
